TY  - JOUR
AU  - Wagenmakers, M.A.E.M.
AU  - Roerink, S.H.P.P.
AU  - Gil, L.
AU  - Plantinga, T.S.
AU  - Smit, J.W.A.
AU  - Netea-Maier, R.T.
AU  - Hermus, A.R.M.M.
PY  - 2015
UR  - https://hdl.handle.net/2066/153629
AB  - OBJECTIVE: Centripetal obesity is associated with systemic low-grade inflammation and an increased cardiovascular risk. Patients in long-term remission of Cushing's syndrome (CS) report persisting abdominal fat accumulation. However, this has previously not been adequately objectified. Therefore, we investigated the adipose tissue distribution and adipocytokine profiles of patients in long-term remission of CS. DESIGN: Cross-sectional case-control study in a tertiary referral centre. PATIENTS: Fifty-eight patients, in remission of CS for at least 5 years, were compared to 58 age-, gender- and BMI-matched healthy control subjects. MEASUREMENTS: Measures of body composition (assessed with clinical evaluation and dual-energy X-ray absorptiometry (DEXA) scanning) and serum adipocytokine profiles. RESULTS: Compared to the matched control subjects, patients in long-term remission of CS had a greater waist circumference (P < 0.01), a smaller thigh circumference (P < 0.01), a higher waist-to-hip ratio (P < 0.01) and a higher hip-to-thigh ratio (P < 0.01). As measured with DEXA scanning, patients had a higher percentage of truncal fat mass (P = 0.01), and the truncal fat mass to leg fat mass ratio was greater (P < 0.01). Patients had lower adiponectin levels (P < 0.01), higher leptin levels (P < 0.01) and higher resistin levels (P = 0.04) than control subjects. CONCLUSION: Even after long-term remission, patients who suffered from CS in the past continue to have a centripetal adipose tissue distribution and an adverse adipokine profile. This is independent of aetiology of the CS, treatment strategies, hormonal deficiencies and comorbidity, and probably contributes to the persistent increased cardiovascular risk.
TI  - Persistent centripetal fat distribution and metabolic abnormalities in patients in long-term remission of Cushing's syndrome
EP  - 187
SN  - 0300-0664
IS  - iss. 2
SP  - 180
JF  - Clinical Endocrinology
VL  - vol. 82
DO  - https://doi.org/10.1111/cen.12639
ER  - 
TY  - JOUR
AU  - Netea-Maier, R.T.
AU  - Kluck, V.
AU  - Plantinga, T.S.
AU  - Smit, J.W.A.
PY  - 2015
UR  - https://hdl.handle.net/2066/154611
AB  - Thyroid cancer is the most common endocrine malignancy. Despite having a good prognosis in the majority of cases, when the tumor is dedifferentiated it does no longer respond to conventional treatment with radioactive iodine, the prognosis worsens significantly. Treatment options for advanced, dedifferentiated disease are limited and do not cure the disease. Autophagy, a process of self-digestion in which damaged molecules or organelles are degraded and recycled, has emerged as an important player in the pathogenesis of different diseases, including cancer. The role of autophagy in thyroid cancer pathogenesis is not yet elucidated. However, the available data indicate that autophagy is involved in several steps of thyroid tumor initiation and progression as well as in therapy resistance and therefore could be exploited for therapeutic applications. The present review summarizes the most recent data on the role of autophagy in the pathogenesis of thyroid cancer and we will provide a perspective on how this process can be targeted for potential therapeutic approaches and could be further explored in the context of multimodality treatment in cancer and personalized medicine.
TI  - Autophagy in thyroid cancer: present knowledge and future perspectives
SN  - 1664-2392
JF  - Frontiers in Endocrinology
VL  - vol. 6
DO  - https://doi.org/10.3389/fendo.2015.00022
L1  - https://repository.ubn.ru.nl/bitstream/handle/2066/154611/154611.pdf?sequence=1
ER  -